<?xml version='1.0' encoding='utf-8'?>
<document id="29779093"><sentence text="Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo." /><sentence text="Finerenone is a selective, non-steroidal mineralocorticoid receptor antagonist"><entity charOffset="0-10" id="DDI-PubMed.29779093.s2.e0" text="Finerenone" /></sentence><sentence text=" In vivo and in vitro studies were performed to assess absolute bioavailability of finerenone, the effect of metabolic enzyme inhibitors on the pharmacokinetics of finerenone and its metabolites, the quantitative contribution of the involved enzymes cytochrome P450 (CYP) 3A4 and CYP2C8 and the relevance of gut wall versus liver metabolism"><entity charOffset="83-93" id="DDI-PubMed.29779093.s3.e0" text="finerenone" /><entity charOffset="164-174" id="DDI-PubMed.29779093.s3.e1" text="finerenone" /><pair ddi="false" e1="DDI-PubMed.29779093.s3.e0" e2="DDI-PubMed.29779093.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29779093.s3.e0" e2="DDI-PubMed.29779093.s3.e1" /></sentence><sentence text="" /><sentence text="The pharmacokinetics, safety and tolerability of finerenone (1"><entity charOffset="49-59" id="DDI-PubMed.29779093.s5.e0" text="finerenone" /></sentence><sentence text="25-10 mg orally or 0" /><sentence text="25-1" /><sentence text="0 mg intravenously) were evaluated in healthy male volunteers in four crossover studies" /><sentence text=" Absolute bioavailability was assessed in volunteers receiving finerenone orally and by intravenous infusion (n = 15) and the effects of erythromycin (n = 15), verapamil (n = 13) and gemfibrozil (n = 16) on finerenone pharmacokinetics were investigated"><entity charOffset="63-73" id="DDI-PubMed.29779093.s9.e0" text="finerenone" /><entity charOffset="137-149" id="DDI-PubMed.29779093.s9.e1" text="erythromycin" /><entity charOffset="160-169" id="DDI-PubMed.29779093.s9.e2" text="verapamil" /><entity charOffset="183-194" id="DDI-PubMed.29779093.s9.e3" text="gemfibrozil" /><entity charOffset="207-217" id="DDI-PubMed.29779093.s9.e4" text="finerenone" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e0" e2="DDI-PubMed.29779093.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e0" e2="DDI-PubMed.29779093.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e0" e2="DDI-PubMed.29779093.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e0" e2="DDI-PubMed.29779093.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e0" e2="DDI-PubMed.29779093.s9.e4" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e1" e2="DDI-PubMed.29779093.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e1" e2="DDI-PubMed.29779093.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e1" e2="DDI-PubMed.29779093.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e1" e2="DDI-PubMed.29779093.s9.e4" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e2" e2="DDI-PubMed.29779093.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e2" e2="DDI-PubMed.29779093.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e2" e2="DDI-PubMed.29779093.s9.e4" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e3" e2="DDI-PubMed.29779093.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29779093.s9.e3" e2="DDI-PubMed.29779093.s9.e4" /></sentence><sentence text=" Finerenone was also incubated with cryopreserved human hepatocytes in vitro in the presence of erythromycin, verapamil or gemfibrozil"><entity charOffset="1-11" id="DDI-PubMed.29779093.s10.e0" text="Finerenone" /><entity charOffset="96-108" id="DDI-PubMed.29779093.s10.e1" text="erythromycin" /><entity charOffset="110-119" id="DDI-PubMed.29779093.s10.e2" text="verapamil" /><entity charOffset="123-134" id="DDI-PubMed.29779093.s10.e3" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.29779093.s10.e0" e2="DDI-PubMed.29779093.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29779093.s10.e0" e2="DDI-PubMed.29779093.s10.e1" /><pair ddi="false" e1="DDI-PubMed.29779093.s10.e0" e2="DDI-PubMed.29779093.s10.e2" /><pair ddi="false" e1="DDI-PubMed.29779093.s10.e0" e2="DDI-PubMed.29779093.s10.e3" /><pair ddi="false" e1="DDI-PubMed.29779093.s10.e1" e2="DDI-PubMed.29779093.s10.e1" /><pair ddi="false" e1="DDI-PubMed.29779093.s10.e1" e2="DDI-PubMed.29779093.s10.e2" /><pair ddi="false" e1="DDI-PubMed.29779093.s10.e1" e2="DDI-PubMed.29779093.s10.e3" /><pair ddi="false" e1="DDI-PubMed.29779093.s10.e2" e2="DDI-PubMed.29779093.s10.e2" /><pair ddi="false" e1="DDI-PubMed.29779093.s10.e2" e2="DDI-PubMed.29779093.s10.e3" /></sentence><sentence text="" /><sentence text="Finerenone absolute bioavailability was 43"><entity charOffset="0-10" id="DDI-PubMed.29779093.s12.e0" text="Finerenone" /></sentence><sentence text="5% due to first-pass metabolism in the gut wall and liver" /><sentence text=" The geometric mean AUC0-∞ ratios of finerenone (drug + inhibitor/drug alone) were 3"><entity charOffset="37-47" id="DDI-PubMed.29779093.s14.e0" text="finerenone" /></sentence><sentence text="48, 2" /><sentence text="70 and 1" /><sentence text="10 with erythromycin, verapamil and gemfibrozil, respectively"><entity charOffset="8-20" id="DDI-PubMed.29779093.s17.e0" text="erythromycin" /><entity charOffset="22-31" id="DDI-PubMed.29779093.s17.e1" text="verapamil" /><entity charOffset="36-47" id="DDI-PubMed.29779093.s17.e2" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.29779093.s17.e0" e2="DDI-PubMed.29779093.s17.e0" /><pair ddi="false" e1="DDI-PubMed.29779093.s17.e0" e2="DDI-PubMed.29779093.s17.e1" /><pair ddi="false" e1="DDI-PubMed.29779093.s17.e0" e2="DDI-PubMed.29779093.s17.e2" /><pair ddi="false" e1="DDI-PubMed.29779093.s17.e1" e2="DDI-PubMed.29779093.s17.e1" /><pair ddi="false" e1="DDI-PubMed.29779093.s17.e1" e2="DDI-PubMed.29779093.s17.e2" /></sentence><sentence text=" The contribution ratio of CYP3A4 to the metabolic clearance of finerenone derived from these values was 0"><entity charOffset="64-74" id="DDI-PubMed.29779093.s18.e0" text="finerenone" /></sentence><sentence text="88-0" /><sentence text="89 and was consistent with estimations based on in vitro data, with the remaining metabolic clearance due to CYP2C8 involvement" /><sentence text="" /><sentence text="Finerenone is predominantly metabolized by CYP3A4 in the gut wall and liver"><entity charOffset="0-10" id="DDI-PubMed.29779093.s22.e0" text="Finerenone" /></sentence><sentence text=" Increases in systemic exposure upon concomitant administration of inhibitors of this isoenzyme are predictable and consistent with in vitro data" /><sentence text=" Inhibition of CYP2C8, the second involved metabolic enzyme, has no relevant effect on finerenone in vivo"><entity charOffset="87-97" id="DDI-PubMed.29779093.s24.e0" text="finerenone" /></sentence><sentence text="" /></document>